TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06047379
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Study: NCT05145413
Drug: Xanomeline and Trospium Chloride Capsules
Normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study: NCT06047379
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Study: NCT06047379
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Study: NCT06047379
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Study: NCT04620733
Drug: Seladelpar 10 mg
Normalized name: seladelpar 10 MG
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
Study: NCT04620733
Drug: Seladelpar 5 mg
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
Study: NCT05335005
Drug: MK-2060
Normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2060 administered via IV infusion
Study: NCT05411081
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00231517
Drug: morphine sulphate in intrasite gel
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06612411
Drug: B. subtilis
Normalized name: Bacillus coagulans/B. subtilis 1 billion cell ORAL TABLET,CHEWABLE
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, 3 times a day, orally taken for one month
Study: NCT06611826
Drug: GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
Study: NCT05758818
Drug: Moxifloxacin (positive control)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
Study: NCT05758818
Drug: Milademetan
Normalized name: Milademetan
DrugBank: Milademetan (DB15257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2
Study: NCT06275087
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
Study: NCT06275087
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
Study: NCT04859946
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04859946
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04859946
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04859946
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT04859946
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05698511
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
Study: NCT05921929
Drug: Fluoroethylnormemantine (FENM)
Normalized name: Fenmetrazin
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
Study: NCT05372614
Drug: Neratinib Maleate
Normalized name: Neratinib Maleate
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05433181
Drug: ACE2 Chewing Gum
Normalized name: ACE2 CAR-NK Cell
DrugBank: NKG2D-ACE2 CAR-NK Cell (DB15727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
Study: NCT05621668
Drug: attIL2-T cells
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT00002197
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04867837
Drug: Octaplex
DrugBank: Prothrombin (DB11311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-factor prothrombin complex concentrate (4F-PCC)
Study: NCT05627362
Drug: Elafibranor 80 mg
Normalized name: elafibranor 80 MG
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05627362
Drug: Elafibranor 120 mg
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05627362
Drug: Placebo Matched to Elafibranor 80 mg
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05627362
Drug: Placebo Matched to Elafibranor 120 mg
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04882098
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive guselkumab as SC injection.
Study: NCT06558682
Drug: Disitamab Vedotin and Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
Study: NCT04748042
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone 1000 mg by mouth per day for approximately 6 months.
Study: NCT04748042
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 5 mg by mouth per day for approximately 6 months.
Study: NCT04748042
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
Study: NCT04796948
Drug: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan liposome in combination with oxaliplatin and 5-FU/LV
Study: NCT05804526
Drug: RC88
Normalized name: RC88
DrugBank: RC88 (DB18697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
Study: NCT05804526
Drug: Sintilimab Injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
Study: NCT06538844
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equivalent volume of isotonic saline control
Study: NCT05478720
Drug: 6-diazo-5-oxo-L-norleucine (DON)
Normalized name: 6-ammonio-L-norleucine
DrugBank: 6-diazo-5-oxo-L-norleucine (DB17537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose
Study: NCT05478720
Drug: 6-diazo-5-oxo-L-norleucine (DON)
Normalized name: 6-ammonio-L-norleucine
DrugBank: 6-diazo-5-oxo-L-norleucine (DB17537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
Study: NCT06562582
Drug: Bisoprolol Oral Tablet
Normalized name: bisoprolol Oral Tablet
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timing of drug intervention after PCI
Study: NCT06562582
Drug: Ramipril Oral Product
Normalized name: ramipril Oral Product
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Timing of drug intervention after PCI
Study: NCT06562582
Drug: Dapagliflozin Oral Product
Normalized name: dapagliflozin Oral Product
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Timing of drug intervention after PCI
Study: NCT05032183
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05032183
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT05032183
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give IV
Study: NCT05065164
Drug: Denosumab Only Product
Normalized name: Denosumab only product
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: denosumab subcutaneous injection /6 months, twice a year
Study: NCT05032183
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05032183
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06558799
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Study: NCT04269902
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05099003
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT06041503
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
Study: NCT06041503
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
Study: NCT06335303
Drug: BI 1819479
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1819479
Study: NCT06678659
Drug: REC-1245
Normalized name: REC-994
DrugBank: REC-994 (DB15616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REC-1245 capsule 1mg, 5mg, 25mg
Study: NCT06676033
Drug: epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Study: NCT05286788
Drug: Binimetinib Oral Tablet [Mektovi]
Normalized name: binimetinib Oral Tablet [Mektovi]
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
Study: NCT06423859
Drug: Articaine
Normalized name: Articaine
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: supraclavicular brachial plexus block with articaine 2%
Study: NCT06423859
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
Study: NCT06643884
Drug: AU-011
Normalized name: Light-activated au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AU-011 Via Suprachoroidal Administration with laser treatment
Study: NCT06325709
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
Study: NCT06325709
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
Study: NCT06325709
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
Study: NCT06325709
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
Study: NCT06528093
Drug: BI 765883
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765883
Study: NCT06528093
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine
Study: NCT06528093
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel
Study: NCT06694454
Drug: azacytidine
Normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.
Study: NCT06694454
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06694454
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06694454
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06694454
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06694454
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT06694454
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study: NCT05996627
Drug: Belumosudil
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05664893
Drug: Ribociclib Oral Tablet
Normalized name: ribociclib Oral Tablet
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance
Study: NCT06247488
Drug: Oxycodone 20 mg
Normalized name: oxycodone 20 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will receive oral dose of oxycodone 20 mg.
Study: NCT06247488
Drug: GE-IR 200 mg
Normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
Study: NCT06247488
Drug: GE-IR 450 mg
Normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
Study: NCT05672173
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05672173
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06083883
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT06226571
Drug: SNDX-5613
Normalized name: anti-Csf1R monoclonal antibody SNDX-6352
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
Study: NCT06045975
Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions.
Study: NCT05038735
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
Study: NCT05038735
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
Study: NCT05038735
Drug: Alpelisib-matching placebo
Normalized name: alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
Study: NCT05255484
Drug: LM-108
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05255484
Drug: An Anti-PD-1 Antibody
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06475196
Drug: Sintilimab (PD-1 inhibitor)
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
Study: NCT05470881
Drug: Atropine Sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of one drop QD on both eyes for 14 days.